Navigation Links
Dr. Paul Greengard, Karolinska Institutet's Bicentennial Gold Medal Recipient

NEW YORK, Sept. 23 /PRNewswire-USNewswire/ -- Dr. Paul Greengard, a Nobel Prize-winning neurobiologist and director of the Fisher Center for Alzheimer's Disease Research at The Rockefeller University, will receive the Karolinska Institutet's Bicentennial Gold Medal on September 23rd, 2010.  This medal is the highest award conferred by Karolinska Institutet during its 200th anniversary celebrations, and recognizes the work of an individual not permanently located at the Karolinska Institutet, who has contributed to the esteemed Swedish university's activities.  Since 1901, the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.

"Dr. Greengard is one of the most prominent scientists of this century," says Harriet Wallberg-Henriksson, President of Karolinska Institutet.  "His seminal work has revealed several of the mechanisms behind psychiatric diseases.  He has been a mentor for generations of Karolinska Institutet scientists, who have been inspired by his scientific leadership and by his extraordinary capacity to reveal the biological meaning and medical implications of a series of unexpected observations from the laboratory."

Dr. Greengard has authored over 1,000 major scientific publications, and on September 2, 2010, he published an article in the scientific journal Nature that has been lauded as a potential paradigm shift in how Alzheimer's will be studied, and possibly treated, in the future. The article, entitled "Gamma-secretase Activating Protein is a Therapeutic Target for Alzheimer's Disease," outlines the discovery of a protein in the brain that stimulates the production of beta-amyloid, a protein in the brain believed to be one of the biological causes of Alzheimer's disease.

Dr. Greengard is a member of the National Academy of Sciences and has received more than 50 awards and honors.  In 2000, Dr. Paul Greengard, together with his wife, the renowned sculptor, Ursula von Rydingsvard, used his Nobel Prize honorarium to fund the Pearl Meister Greengard Prize, an award for women scientists named in honor of Greengard's mother, Pearl Meister Greengard, who died giving birth to him. The award is to combat discrimination against women in science, since, as Greengard observed, "Women are not yet receiving awards and honors at a level commensurate with their achievements."

The Karolinska Institutet's Gold Medal will be presented to Greengard on September 23rd at the residence of the Swedish ambassador to the United States in Washington, D.C.

Mr. Kent L. Karosen, President and CEO of the Fisher Center for Alzheimer's Research Foundation adds, "On behalf of the Fisher Center Foundation, I want to congratulate Dr. Greengard on this very prestigious award.  Dr. Greengard's contribution to Alzheimer's research has shaped the course of modern investigation into the causes and possible treatment of the disease, and his recent findings continue to open new avenues of study.  We are honored to have such a world prominent scientist directing the work of our research center."  

The Fisher Center for Alzheimer's Research Foundation is a leading source of funding for Alzheimer's research and education. We serve Alzheimer's patients and their families by seeking to understand the causes of, discover a cure for, and improve the lives of people with Alzheimer's disease.  Nobel laureate Dr. Paul Greengard directs the Foundation's team of internationally renowned scientists.  Of the money raised by the Foundation, only 8 cents out of every dollar is used for overhead and administrative purposes.  For more information about the Fisher Center for Alzheimer's Research Foundation, visit

SOURCE Fisher Center for Alzheimer’s Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
2. Karolinska Development and Kurma Biofund to Enter Strategic Partnership
3. Karolinska Development and Uminova Invest Sign Co-operation Agreement
4. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
5. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
6. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
7. Karolinska Development Closes Fully Subscribed New Share Issue
8. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
9. Genetics Entrepreneur Jonathan Rothberg Wins CT Medal of Technology
10. J. Craig Venter, Ph.D. to Receive National Medal of Science From President Obama
11. 7-Time Olympic Medalist Shannon Miller Endorses StemCyte
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
Breaking Biology News(10 mins):